Are Transfusions a Barrier to High-Quality End-of-Life Care in Hematology?
Dr. LeBlanc and Dr. Litzow take a look at an issue within the field consisting of hematologists referring their patients to hospice late or not at all even when there are s
Venous Thrombosis on One Side and Bleeding on the Other: How to Walk the Fence in Cancer Patients With Thrombosis and Thrombocytopenia
Dr. Linkins provides guidance on how to manage recurrent thrombosis and bleeding in a cancer patient with severe thrombocytopenia that develops VTE.
Insightful critiques and informed commentary of important ongoing clinical trials
Drs. Sklavenitis Pistofidis and Ghobrial discuss a study that looks at a targeted approach to therapy for multiple myeloma patients carrying a t(1;14) translocation.
Dr. Moss discusses the CLARITY study, which looks at the combination of therapies venetoclax and ibrutinib to treat relapsed/refractory chronic lymphocytic leukemia.
Dr. Moll discusses a study that looks at the use of direct oral anticoagulants in patients with definite antiphospholipid syndrome.
Dr. Jacobson looks at a study that investigates the safety and efficacy of chimeric antigen receptor (CAR)- T cell therapy with KTE-C19 in combination with the anti-PD-L1 antibody atezolizumab in patients with refractory DLBCL.
Dr. Abdel-Wahab and Dr. Taylor look at a study that evaluates the safety of combining the anti-PD-L1 antibody atezolizumab with the novel hypomethylating agent guadecitabine in older adults with AML not eligible for standard induction therapy.
Dr. Keel breaks down a study that looks at the use and effects of two different doses of intravenous iron in patients with chronic kidney disease on hemodialysis.
Dr. Roberts looks at whether chemoimmunotherapy can be improved as a front-line therapy for chronic lymphocytic leukemia in fit patients.
Dr. Linkins covers a study that compares apixaban with no anticoagulants for prevention of a composite of fatal and nonfatal venous thromboembolism in children with a central venous catheter and newly diagnosed ALL, lymphoma or mixed-phenotype acute leukemia.
Drs. Raetz and Kovacsovics cover a trial meant to develop a precision medicine approach for the treatment of AML.
Dr. Moss covers a study that compares the PD-1 inhibitor pembrolizumab with brentuximab vedotin in subjects with relapsed or refractory classical HL.
July-August 2018Volume 15, Issue 4
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology